Case 1:13-cv-01461-RGA Document 93 Filed 05/28/14 Page 1 of 2 PageiD #: 1234
`
`"\~. AO 120 (Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § I I 16 you are hereby advised that a court action has been
`on the following X Patents or
`
`Trademarks:
`
`filed in the U.S. District Court
`
`Delaware
`
`DOCKET NO.
`13cv1461-RGA
`PLAINTIFF
`
`DATE FILED
`8/20/2013
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`DISTRICT OF DELAWARE
`
`Reckitt Benckiser Pharmaceuticals Inc., et al.
`
`Par Pharmaceutical Inc., et al.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`8,475,832
`
`8,017,150
`
`7/2/2013
`
`9/13/2011
`
`HOLDER OF PATENT OR TRADEMARK
`
`RB Pharmaceuticals Limited
`
`Mo noSol RX LLC
`
`8,603,514
`
`12/10/2013
`
`MonoSol RX LLC
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`0 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 CrossBill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`See attached Order
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`JOHN A. CERINO, CLERK OF COURT
`
`DATE
`
`5/28/2014
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`
`
`Page 1
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-02003-RGA Document 62 Filed 05/09/14 Page 1 of 2 PageiD #: 738
`
`<\lb AO 120 (Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`X Patents or
`
`filed in the U.S. District Court ____ ---"D~e""la::.:w'"'a"'re:::.._ ____ on the following
`
`Trademarks:
`
`DOCKET NO.
`13cv2003-RGA
`PLAINTIFF
`
`DATE FILED
`12/6/2013
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`DISTRICT OF DELAWARE
`
`Reckitt Benckiser Pharmaceuticals Inc., et a!.
`
`Alvogen Pine Brook Inc., eta!.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`8,475,832
`
`8,017,150
`
`7/2/2013
`
`9/13/2011
`
`HOLDER OF PATENT OR TRADEMARK
`
`RB Pharmaceuticals Limited
`
`Mo noSol RX LLC
`
`8,603,514
`
`12/10/2013
`
`MonoSol RX LLC
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENTOR
`TRADEMARK NO.
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`D Answer
`
`D Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`See attached Order
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`JOHN A. CERINO, CLERK OF COURT
`
`DATE
`
`5/9/2014
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`
`
`Page 2
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:14-cv-00422-UNA Document 4 Filed 04/04/14 Page 1 of 1 PageiD #: 180
`
`AO 120 (Rev. 08110)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`DELAWARE
`on the following
`filed in the U.S. District Court
`0 Trademarks or
`0 Patents.
`( 0 the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`4/4/2014
`
`U.S. DISTRICT COURT
`
`DELAWARE
`
`DEFENDANT
`PLAINTIFF
`PAR PHARMACEUTICAL, INC. and INTELGENX
`RECKITT BENCKISER PHARMACEUTICALS INC., RB
`PHARMACEUTICALS LIMITED, and MONOSOL RX LLC TECHNOLOGIES CORP.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,475,832
`
`2 8,017,150
`
`3 8,603,514
`
`4
`
`5
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol RX, LLC
`
`12/10/2013
`
`MonoSol RX, LLC
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`I DECISION/JUDGEMENT
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`I (BY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`
`Page 3
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01461-RGA Document 57 Filed 02/18/14 Page 1 of 1 PageiD #: 632
`
`AO 120 (Rev. 08/10}_
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`of Delaware
`on the following
`filed in the U.S. District Court
`~Patents. ( 0 the patent action involves 35 U.S.C. § 292.):
`D Trademarks or
`
`DATE FILED
`8/20/2013
`
`U.S. DISTRICT COURT
`
`DOCKET NO.
`13-cv-1461-RGA
`DEFENDANT
`PLAINTIFF
`PAR PHARMACEUTICAL, INC., INTELGENX
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC, TECHNOLOGIES CORP., and L TS LOHMANN THERAPY
`SYSTEMS CORP.
`
`of Delaware
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`l U.S. 8,475,832
`
`2 U.S. 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`DATE IN2JWJ2n~ 4
`
`PATENTOR
`TRADEMARK NO.
`I u.s. 8,603,514
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`INCLUDED BY
`
`~Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`12/10/2013
`
`MonoSol RX, LLC
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`IDECISIONIJUDGEMEN r
`
`I (RY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4---Case file copy
`
`
`Page 4
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01674-RGA Document44 Filed 02/18/14 Page 1 of 1 PageiD #: 603
`
`AO 120 (Rev. 08110)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U .S.C. § 290 and/or I 5 U.S.C. § ll I 6 you are hereby advised that a court action has been
`of Delaware
`on the following
`filed in the U.S. District Court
`D Trademarks or
`~Patents. ( D the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`13-cv-167 4-RGA
`DEFENDANT
`PLAINTIFF
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB WATSON LABORATORIES, INC.
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC,
`
`of Delaware
`
`DATE FILED
`10/8/2013
`
`U.S. DISTRICT COURT
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,475,832
`
`7/2/2013
`
`RB Pharmaceuticals Limited
`
`2 U.S. 8,017,150
`
`9/13/2011
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE~7WBm4
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`~Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`D Answer
`
`D Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,603,514
`
`12/10/2013
`
`MonoSol RX, LLC
`
`2
`
`3
`
`4
`
`5
`
`I DECISION/JUDGEMENT
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`!'BY) DEPIITY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patcnt(s), mail this copy to Director Copy 4-Case file copy
`
`
`Page 5
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES pATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www .uspto.gov
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8603514
`
`1199-4B CIP
`
`5059
`
`APPLICATION NO.
`
`11/775,484
`
`23869
`7590
`Hoffmann & Baron LLP
`6900 Jericho Turnpike
`Syosset, NY 11791
`
`ISSUE DATE
`
`12/10/2013
`
`11/20/2013
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 779 day(s). Any patent to issue from the above-identified application will
`include an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Robert K. Yang, Flushing, NY;
`Richard C. Fuisz, McLean, VA;
`Garry L. Myers, Kingsport, TN;
`Joseph M. Fuisz, Washington, DC;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`
`Page 6
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 12/15/2010
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`11775484
`
`2007-07-10
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1615
`
`Examiner Name
`
`I Mercier, Melissa S.
`
`Attorney Docket Number
`
`1199-4 8 CIP
`
`11775484- GAU: 1615
`
`/MM/ 9
`
`6660292
`
`82
`
`2003-12-09
`
`Zerbe et al.
`
`/MM/
`
`10
`
`6,800,)29
`
`82
`
`2004-10-05
`
`Horstmann et al.
`
`rh/M~v1/(
`~· ange s llpplie :£824829
`o docum( nt,
`vf.A.F /
`1/MfifOl JJ2
`
`7005142
`
`82
`
`2004-11-30
`
`Berry et al.
`
`82
`
`2006-02-28
`
`Leon et al.
`
`/M~111/
`
`13
`
`7579019
`
`82
`
`2009-08-25
`
`Tapolsky et al.
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`I Add
`I
`I Remove I
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`/MM/
`
`1
`
`2
`
`20050048102
`
`A1
`
`2005-03-03
`
`Tapolsky et al.
`
`20070148097
`
`A1
`
`2007-06-28
`
`Finn et al.
`
`/MM/
`If you wish to add additional U.S. Published Application citation information please click the Add button .I Add
`I
`IRemovel
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`No Number3
`Initial*
`
`Country
`Code2 i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`T5
`
`EFS Web 2.1.17
`
`/Melissa Mercier/ (01/21/2011)
`
`
`Page 7
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 01/29/2008
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`11775484
`
`2007-07-10
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1615
`
`Examiner Name
`
`I Unassigned
`
`Attorney Docket Number
`
`1199-48 CIP
`
`11775484- GAU: 1615
`
`9
`
`5455043
`
`1995-10-03
`
`Fischei-Ghodsian
`
`10
`
`5462749
`
`1995-10-31
`
`Rencher
`
`11
`
`c jlange(s) 2 pplie<
`
`t c documen,
`/ f.A.F/
`1V7/2ol;:.
`
`12
`
`5472704
`
`1995-12-05
`
`Santus, et al.
`Ciai'ISBPie ct al.
`
`5518902
`
`1996-05-12
`
`Ozaki et al.
`
`13
`
`5567431
`
`1996-10-22
`
`Vert et al.
`
`14
`
`5620757
`
`1997-04-15
`
`Ninomiya et al.
`
`15
`
`5629003
`
`1997-05-13
`
`Horstmann et al.
`
`16
`
`5700478
`
`1997-12-23
`
`Biegajski et al.
`
`17
`
`5700479
`
`1997-12-23
`
`Lundgren
`
`18
`
`5766620
`
`1998-06-16
`
`Herber et al.
`
`19
`
`5948430
`
`1999-09-07
`
`Zerbe et al.
`
`EFSWeb2.0.2
`
`/IVIe ISSa IVIercler/ {V_~N;2!_c~l:~:
`ALL REFERENC S CONSIDERED EXCEPT WHERE LINED THROUGH. /MM i
`
`
`Page 8
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 01/29/2008
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`11775484
`
`2007-07-10
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1615
`
`Examiner Name
`
`I Unassigned
`
`Attorney Docket Number
`
`1199-48 CIP
`
`11775484- GAU: 1615
`
`42
`
`4438258
`
`1984-03-20
`
`Graham
`
`43
`
`4460562
`
`1984-07-17
`
`Keith et al.
`
`44
`
`4466973
`
`1984-08-21
`
`Rennie
`
`45
`
`4503070
`
`1985-03-05
`
`Eby
`
`46
`
`c range(s) 2 pplie<
`
`4515162
`
`Yamamoto, et al.
`
`1985-05-07
`
`~!!!l!i!~llile!
`
`t c documen,
`/ f.A.f /
`1V7/2ol?
`
`47
`
`4517173
`
`1985-05-14
`
`Kizawa et al.
`
`48
`
`4529601
`
`1985-07-16
`
`Broberg et al.
`
`49
`
`4529748
`
`1985-07-16
`
`Wienecke
`
`50
`
`4562020
`
`1985-12-31
`
`Hijiya et al.
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`I
`I Add
`I Remove I
`
`Examiner Cite
`Initial*
`No
`
`Publication Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`/Melissa Merc1er/ \09103/201 0)
`'
`'
`'
`
`EFS Web 2.0.2
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/
`
`
`Page 9
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 01/29/2008
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`11775484
`
`2007-07-10
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1615
`
`Examiner Name
`
`I Unassigned
`
`Attorney Docket Number
`
`1199-48 CIP
`
`11775484- GAU: 1615
`
`31
`
`4925670
`
`1990-05-15
`
`Schmidt
`
`32
`
`4927634
`
`1990-05-22
`
`Sorrentino et al.
`
`33
`
`4927636
`
`1990-05-22
`
`Hijiya et al.
`
`34
`
`4937078
`
`1990-06-26
`
`Mezei et al.
`
`35
`
`4940587
`
`1990-07-10
`
`Jenkens et al.
`
`36
`
`4948580
`
`1990-08-14
`
`Browning
`
`37
`
`4958580
`
`1990-09-25
`
`Asaba et al.
`
`38
`
`4978531
`
`1990-12-18
`
`Yamazaki, et al.
`-"ei IEs e:t al.
`
`c lh~ncr,..( "''\ ·~~l; ... ~
`1rr
`0
`tc documen ,
`39
`'f .A.F /
`/
`11 /7/201)
`
`4981693
`
`1991-01-01
`
`Higashi et al.
`
`40
`
`4981875
`
`1991-01-01
`
`Leusner et al.
`
`41
`
`5023082
`
`1991-06-11
`
`Friedman et al.
`
`EFS Web 2.0.2
`
`iMelissa Me rcier/ (09/03i201 01
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/
`
`
`Page 10
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 01/29/2008
`
`1177~Jcma~: 1615
`
`Approved for use through 1113012007. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`11775484
`
`2007-07-10
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1615
`
`Examiner Name
`
`I Unassigned
`
`Attorney Docket Number
`
`1199-48 CIP
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Cadet
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`I Remove I
`
`1
`
`4569837
`
`1986-02-11
`
`Suzuki et al.
`
`2
`
`4593053
`
`1986-06-03
`
`Jevne
`
`3
`
`4608249
`
`1986-08-26
`
`Otsuka et al.
`
`4
`
`4615697
`
`1986-10-07
`
`Robinson
`
`5
`
`4623394
`
`1986-11-18
`
`Nakamura et al.
`
`6
`
`4652060
`
`1987-03-24
`
`Miyake
`
`7
`
`4659714
`
`1987-04-21
`
`Watt-Smith
`
`8
`
`4675009
`
`c ~ange(s) <c pplie ~
`
`to document
`/f.A.F /
`11/7/201)
`EFS Web 2.0.2
`
`june 2), 1 '} ~7
`Hymes et al.
`~QIJJ QJ 2§
`
`/Melissa Mercier/ (09/03/201 0)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/
`
`
`Page 11
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`APPLICATION
`NUMBER
`11/775,484
`
`FILING or
`37l(c)DATE
`07/10/2007
`
`FIL FEE REC'D
`8083
`
`23869
`Hoffmann & Baron LLP
`6900 Jericho Turnpike
`Syosset, NY 11791
`
`Ul\TfED STI\TES DEPA RTME'IT OF COMMERCE
`United States Patent and Trademark Office
`Adill"'· COMMISSIO'JER FOR PATENTS
`PO Box 1450
`Alexandria, Virgmia 22313-1450
`\VVi\V.USpto.gov
`
`ATTY.DOCKET.NO
`1199-4B CIP
`
`6
`34
`CONFIRMATION NO. 5059
`CORRECTED FILING RECEIPT
`
`IIIIIIIIIIIIIIIIIIIIIIII]~!I]~~~~~~~~Ui~~~~~~ ~I] 11111111111111111111111
`
`Date Mailed: 11/04/2013
`
`Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination
`in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the
`application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE,
`NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the
`changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit
`any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply
`to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections
`
`lnventor(s)
`
`Robert K. Yang, Flushing, NY;
`Richard C. Fuisz, Mclean, VA;
`Garry L. Myers, Kingsport, TN;
`Joseph M. Fuisz, Washington, DC;
`
`Applicant( s)
`
`Robert K. Yang, Flushing, NY;
`Richard C. Fuisz, Mclean, VA;
`Garry L. Myers, Kingsport, TN;
`Joseph M. Fuisz, Washington, DC;
`Assignment For Published Patent Application
`MONOSOLRX LLC, Portage, IN
`
`Power of Attorney: The patent practitioners associated with Customer Number 23869
`
`Domestic Priority data as claimed by applicant
`This application is a CIP of 10/768,809 01/30/2004 PAT 7357891
`which claims benefit of 60/443,741 01/30/2003
`and is a CIP of PCT/US02/32575 10/11/2002
`which claims benefit of 60/386,937 06/07/2002
`and is a CIP of 10/074,272 02/14/2002 PAT 7425292
`which claims benefit of 60/328,868 10/12/2001
`and said 10/768,809 01/30/2004
`is a CIP of PCT/US02/32594 10/11/2002
`which claims benefit of 60/414,276 09/27/2002
`and claims benefit of 60/386,937 06/07/2002
`and is a CIP of 10/074,272 02/14/2002 PAT 7425292
`page 1 of 4
`
`
`Page 12
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`which claims benefit of 60/328,868 10/12/2001
`and said 10/768,809 01/30/2004
`is a CIP of PCT/US02/32542 10/11/2002
`which claims benefit of 60/371,940 04/11/2002
`and claims benefit of 60/386,937 06/07/2002
`and is a CIP of 10/074,272 02/14/2002 PAT 7425292
`This application 11/775,484
`is a CIP of 10/856,176 05/28/2004 PAT 7666337
`which claims benefit of 60/473,902 05/28/2003
`and is a CIP of 10/768,809 01/30/2004 PAT 7357891
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
`Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to
`foreign priority. See 37 CFR 1.55 and 1.76.
`
`If Required, Foreign Filing License Granted: 09/12/2007
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 11/775,484
`Projected Publication Date: Not Applicable
`Non-Publication Request: No
`Early Publication Request: No
`Title
`
`UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING
`COMPOSITIONS
`
`Preliminary Class
`
`424
`
`Statement under 37 CFR 1.55 or 1.78 for AlA (First Inventor to File) Transition Applications:
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application
`page 2 of 4
`
`
`Page 13
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HAL T (1-866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`page 3 of 4
`
`
`Page 14
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Select USA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call
`+ 1-202-482-6800.
`
`page 4 of 4
`
`
`Page 15
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`PATENT
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Applicants:
`
`Yang et al.
`
`Examiner:
`
`Melissa S. Mercier
`
`Application No.:
`
`111775,484
`
`Group Art Unit:
`
`1615
`
`Filed:
`
`July 10, 2007
`
`Docket:
`
`1199-4B CIP/RCE
`
`Confirmation No.
`
`5059
`
`Dated:
`
`November 1, 2013
`
`For:
`
`UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM
`INCORPORATING TASTE-MASKING COMPOSITIONS
`
`Mail Stop Issue Fee
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`Certificate of EFS-Web Transmission
`I hereby certify that this correspondence is being transmitted to the
`U.S. Patent and Trademark Office via the Office's electronic filing
`system.
`
`Dated: November 1, 2013
`
`Signatnre: Stephen J. Brown /Stephen J. Brown!
`
`REQUEST FOR CORRECTION OF
`APPLICATION FILING RECEIPT
`
`Madam:
`
`In reviewing the Corrected Filing Receipt mailed October 30, 2013, for the
`
`above-identified application, we uncovered errors in the section entitled "Domestic Priority data
`
`as claimed by applicant." In particular, the domestic priority listed on the Corrected Filing
`
`Receipt does not match that recited in Cross-Reference to Related Applications as amended in
`
`the Amendment After Allowance filed October 6, 2013. (See Amendments to the Specification,
`
`p. 2.)
`
`The Patent Office appears to be responsible for these errors. Accordingly, we ask that
`
`corrections be made to the Filing Receipt as indicated below.
`
`
`Page 16
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Application No. 111775,484
`Request for Corrected of Application Filing Receipt
`Docket No.: 1199-4B CIP/RCE
`Page 2
`
`The requested corrections are shown below - deletions are shown as a strikethrough and
`
`additions are underlined (for clarity the corrected lines are in boldface).
`
`This application is a CIP of 101768,809 01/30/2004 PAT 7357891
`
`which claims benefit of 60/443,741 01/30/2003
`
`and is a CIP of PCT/US02/32575 10111/2002
`
`which claims benefit of 60/386,937 06/07/2002
`
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`
`and said 101768,809 01/30/2004
`
`is a CIP of PCT/US02/32594 10111/2002
`
`which claims benefit of 60/414,276 09/27/2002
`and claims benefit of 60/386,937 06/07/2002
`
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`
`and said 101768,809 01/30/2004
`
`is a CIP of PCT/US02/32542 10111/2002
`whieh elaims beaefit of 601328,868 1(-)!12/2(-)(-)1
`which claims benefit of 60/386,937 06/07/2002
`and claims benefit of 60/371,940 04/11/2002
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`This application 111775,484
`
`is a CIP of 10/856,176 05/28/2004 PAT 7666337
`
`which claims benefit of 60/473,902 05/28/2003
`
`and is a CIP of 101768,809 01/30/2004 PAT 7357891
`
`
`Page 17
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Application No. 111775,484
`Request for Corrected of Application Filing Receipt
`Docket No.: 1199-4B CIP/RCE
`Page 3
`
`Attached is a copy of the original filing receipt with the above referenced corrections
`
`noted therein.
`
`To aid the Office, a clean version of the Domestic Priority data as claimed by the
`
`applicant is presented below:
`
`This application is a CIP of 101768,809 01/30/2004 PAT 7357891
`
`which claims benefit of 60/443,741 01/30/2003
`
`and is a CIP of PCT/US02/32575 10111/2002
`
`which claims benefit of 60/386,937 06/07/2002
`
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`
`and said 101768,809 01/30/2004
`
`is a CIP of PCT/US02/32594 10111/2002
`
`which claims benefit of 60/414,276 09/27/2002
`
`and claims benefit of 60/386,937 06/07/2002
`
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`
`and said 101768,809 01/30/2004
`
`is a CIP of PCT/US02/32542 10111/2002
`
`which claims benefit of 60/386,937 06/07/2002
`
`and claims benefit of 60/371,940 04111/2002
`
`and is a CIP of 10/074,272 02114/2002 PAT 7425292
`
`which claims benefit of 60/328,868 10112/2001
`
`This application 111775,484
`
`is a CIP of 10/856,176 05/28/2004 PAT 7666337
`
`which claims benefit of 60/473,902 05/28/2003
`
`and is a CIP of 101768,809 01/30/2004 PAT 7357891
`
`
`Page 18
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Application No. 111775,484
`Request for Corrected of Application Filing Receipt
`Docket No.: 1199-4B CIP/RCE
`Page 4
`
`In view of the above, correction of the Filing Receipt is respectfully requested. If any
`
`fees are required, please charge to Deposit Acc